

H.U.GROUP CORPORATE PROFILE

OUR MISSION

Create new value in healthcare and thereby contribute to human health and the future of medical care

H.U. Group provides peace of mind to individuals
across a wide range of healthcare settings.
We will create new value that contributes to
your health and future happiness.



Commitment as a Healthcare Infrastructure Provider

Support testing.
Support surgeries

Innovation Based on Science and Technology

Creating new value for
Japan and the world

Business Model Based on Partnership

Delivering Valuable Products
Globally and Bringing Global
Innovation to Japan



Please click for more details >



OUR
MISSION

TOP MESSAGE

HISTORY

OUR GLOBAL
EXPANSION

OUR
STRATEGY

OUR BUSINESS &
SOURCES OF
VALUE CREATION

ABOUT
H.U.GROUP

CORPORATE
PROFILE



TOP MESSAGE

Healthcare Powered by Innovation, Opening New Paths to the World

For more than 75 years, H.U. Group has been committed to advancing healthcare and diagnostics. Based on the strong foundation we have established, we will achieve further growth on next stage.

As a Group grounded in innovation, we create value from a global perspective. Through our sustainable growth and contributions to society, we will continue to expand the possibilities of healthcare and diagnostics.

Goki Ishikawa

Director, Representative Executive Officer, President and Group CEO
H.U. Group Holdings, Inc.

Named to TIME's 2026 TIME100 Health List of the World's Most Influential Leaders in Health

Goki Ishikawa was named to the 2026 TIME100 Health list of the world's most influential leaders in health. This recognition reflects his contributions to advancing the development of less invasive blood-based testing, expanding the potential for earlier diagnosis and treatment of Alzheimer's disease.

[TIME's special feature page] <https://time.com/collections/time100-health-2026/>

HISTORY

1950-2009

PICK UP INNOVATION

1966 FUJIREBIO INC. Launch of the world's first clinical reagent for syphilis (TPHA)

Commenced the manufacture and sale of diagnostic reagents. Fujirebio's first diagnostic reagent product was the world's first clinical testing reagent for syphilis, for which no highly reliable diagnostic method was available at the time.



PICK UP INNOVATION

1992 FUJIREBIO INC. Launch of "LUMIPULSE® 1200", the fully automated CLEIA testing instrument

Achieved the automation of immunoassay testing, which had previously been performed manually in Japan, and made high-sensitivity measurements possible.



1950

Fujizoki Pharmaceutical. established

Founded on December 18, 1950, in Tokyo, to manufacture and sell pharmaceutical products.

1983

Company name changed to FUJIREBIO INC.

1987

Listed on the 1st Section of the Tokyo Stock Exchange

1998

Acquisition of Centocor Diagnostics of Pennsylvania, Inc. (US) (currently Fujirebio Diagnostics, Inc.)

Acquired the diagnostics division of Centocor Inc., followed by the expansion into overseas raw material supply and CDMO business.



2000

Divestment of pharmaceutical division Focused on the diagnostics business.

2005

Miraca Holdings, Inc. established



1970

Tokyo Special Reference Laboratory, Inc. established

Leveraging its IVD expertise to diversify its business, began providing clinical lab-testing services specializing in esoteric testing. Later, the company broadened its scope to include general testing and grew into Japan's largest provider of clinical lab-testing services.



1989

Company name changed to SRL, Inc.

1995

Genetic and Chromosome Analysis Center established

An analysis center specializing in genetic and chromosomal testing, established in response to the growing demand for commissioned genetic and chromosomal testing services launched in 1987.



2001

Listed on the 1st Section of Tokyo Stock Exchange

PICK UP TOPICS

1987 SRL, Inc.

First in Japan to acquire CAP (College of American Pathologists) accreditation

To advance its globalization efforts, SRL received accreditation from CAP (College of American Pathologists) and became the first laboratory in Japan to receive CAP accreditation with the designation of "Excellent Laboratory."



1987

Nihon Stery, Inc. established

1991

Launch of the on-site sterilization business

In addition to the existing off-site sterilization services, in response to customer needs, we launched on-site services for the cleaning, sterilization, and management of medical equipment.

HISTORY

2010-

PICK UP INNOVATION

2020 FUJIREBIO INC.
Introduced Japan's first and the world's first COVID-19 antigen testing products
 "ESPLINE® SARS-CoV-2" received marketing approval as Japan's first qualitative antigen test, followed by "Lumipulse® SARS-CoV-2 Ag," which received marketing approval as world's first quantitative antigen test.

- **2010**
Acquisition of Innogenetics N.V. (Belgium)
 (currently Fujirebio Europe N.V.)



- **2017**
Miraca Research Institute G.K. (currently H.U. Group Research Institute G.K.) established
- **2017**
Fujirebio Holdings, Inc. established



- **2010**
Acquisition of Nihon Rinsho, Inc.
- **2011**
Acquisition of Tsuchiya Enterprise, Inc.
 (later in 2012, HOKUSHIN Clinical Laboratory, Inc.)
- **2011**
Acquisition of GUNMA Clinical-Laboratory Information Center Inc.
 (later in 2018, SRL KITAKANTO Laboratory Inc.)

2020

Company name changed to H.U. Group Holdings, Inc.

Expanded its business scope as a healthcare group.

- **2022**
Acquisition of ADx NeuroSciences N.V. (Belgium)
 (currently Fujirebio Europe N.V.) and Fluxus, Inc. (US)

2023

Commenced full-scale operations at the H.U. Bioness Complex

It is one of the world's largest clinical testing laboratories and a core facility of the H.U. Group, with an R&D facility on site. It has automated most of the testing process.



- **2025**
Integration of Three Companies in the Lab Testing and its related Services (LTS) Business
 Nihon Rinsho, Inc. absorbed and merged with HOKUSHIN Clinical Laboratory and KITAKANTO Laboratory.

PICK UP TOPICS

2018
Launch of home healthcare and care business centered on home-visit nursing



PICK UP TOPICS

2020-2021 SRL, Inc.
Provision of COVID-19 testing service at major airports in Japan

Became the first private-sector company in Japan to begin providing commissioned SARS-CoV-2 PCR testing services. In addition, conducted quarantine testing at airports with increasing international arrivals, contributing to border control measures.

PICK UP TOPICS

2024
StarQ GAIA Inc. established
 StarQ Care Inc. and GAIA medicare Inc. became subsidiaries. Expanded home healthcare and care business, primarily focused on home-visit nursing, and enhanced service quality.



Driving Innovation through Our Technological Expertise and Development Capabilities

The H.U. Group is engaged in R&D activities to provide new value, looking ahead to the medical and healthcare needs of the future. Leveraging the technological expertise and development capabilities cultivated across our businesses over many years, we continue to create diagnostic and testing technologies that address unmet medical needs in various disease areas, including oncology (cancer), NEURO (neurological diseases), and infectious diseases. One example of these efforts is the Fujirebio Group's work on Alzheimer's disease research. At a time when no effective treatments were available, we were among the first to begin developing diagnostic technologies for the disease. Following the development and launch of Alzheimer's disease-related diagnostic reagents in 1995, we have continued our R&D activities in the NEURO field for more than 30 years.



Blood-based in vitro diagnostic test intended to aid in the diagnosis of Alzheimer's disease

Blood-Based Alzheimer's Disease Diagnostic Reagent — First in the World to Receive U.S. FDA Clearance

In May 2025, a diagnostic reagent that measures the pTau217/ β -Amyloid 1-42 plasma ratio became the world's first blood-based in vitro diagnostic test to receive clearance from the U.S. Food and Drug Administration (FDA) to aid in identifying patients with amyloid pathology associated with Alzheimer's disease. Compared with previously used methods such as cerebrospinal fluid (CSF) testing, this simple and minimally invasive blood test enables treatment decision-making with less burden on patients. In addition, in 2026, the pTau217 measurement reagent obtained CE marking under the Regulation on in vitro diagnostic medical devices (IVDR) in Europe. Through collaboration with organizations around the world, we are accelerating the expansion of our product portfolio in the NEURO field, including Alzheimer's disease and other neurological disorders.

OUR GLOBAL EXPANSION

Toward a Global H.U. Group

H.U. Group aims to achieve growth in global markets by leveraging its unique technological capabilities and strong customer base in Japan.

By building partnerships with global healthcare companies across various segments, including pharmaceutical companies, diagnostic reagent manufacturers, life science companies, and medical device manufacturers, we will bring new value developed in-house to the world while bringing new value developed overseas to Japan. Diseases and healthcare know no borders.

H.U. Group will continue to take on challenges to address unmet medical needs in healthcare and for patients across countries and regions.

Selected by TIME as One of the World's
Most Impactful Companies

H.U. Group was named to TIME's "World's Most Impactful Companies of 2026," a global ranking that scientifically evaluates the tangible impact that companies' products and services have on society and the environment. H.U. Group was recognized among the 500 companies worldwide creating the greatest positive impact.

[TIME's special feature page]

<https://time.com/article/2026/05/12/worlds-most-impactful-companies-2026/>




SUPPORTING EVERY STEP OF THE PATIENT JOURNEY

OUR STRATEGY


Group Strategy by Disease Areas

At H.U. Group, we support patients throughout their entire Patient Journey, from disease prevention and diagnosis to treatment and recovery, leveraging the strengths of each group company to solve unmet medical needs. For disease areas such as cancer and dementia, where the number of patients is increasing globally and becoming a major social issue, we are developing disease-specific strategies across the H.U. Group to contribute to meeting the needs for diagnosis and treatment.




Consolidated Revenue by Disease (FY2025)

Note: Only patents for which the target diseases have been specified are categorized.



Number of Patents Held for Diagnostic Reagents by Disease

*Number of patents held by the Fujirebio Group (as of June 2026)
Note: Only patents for which the target diseases have been specified are categorized.



H.U. Group operates businesses across a wide range of disease areas, including oncology and NEURO as growth areas, as well as infectious diseases as a strategic focus area. In particular, the Fujirebio Group holds patents related to diagnostic reagents in multiple disease areas, including these fields, and is advancing research and development aligned with its disease-specific strategies.



DISEASE-SPECIFIC STRATEGIES Growth Area

Oncology

Supporting Patient Journey from Early Detection to Post-Treatment

With populations aging worldwide and cancer remaining the leading cause of death in Japan, early detection, personalized medicine, and post-treatment monitoring are increasingly important. H.U. Group draws on the strengths of its businesses to support cancer care, from early detection and treatment through diagnostic testing to post-treatment monitoring.

- Supply of Tumor Marker Reagents for Early Detection and Treatment Response Monitoring in Japan and Overseas
- Supporting Treatment Decision-Making through Cancer Panel Testing
- Medical Device Sterilization and Operating Room Support



DISEASE-SPECIFIC STRATEGIES Growth Area



NEURO

Supporting Early Detection of Dementia and Better Living

The number of people with dementia continues to increase as the global population ages, and the large number of undiagnosed potential patients makes dementia a major challenge that must be addressed by society as a whole.

In this field, H.U. Group provides patient-centered services tailored to the needs of each individual by offering blood-based tests for early detection with consideration for patients' physical burden, as well as post-treatment care and other support services.

- Development of Diagnostic Reagents to Aid in the Diagnosis of Alzheimer's Disease
- Supporting Diagnosis through Clinical Lab-Testing Services
- Home-Based Care through Home-Visit Nursing



DISEASE-SPECIFIC STRATEGIES

Focus Area

Infectious Diseases

Addressing Infectious Diseases with Expertise Cultivated Over Many Years

Infectious diseases affect people's lives regardless of time or region, and their spread can cause significant social and economic losses. Preparing for the emergence of new infectious diseases and their resurgence remains an important challenge that must be addressed by society as a whole. Since launching the world's first syphilis diagnostic reagent in 1966, H.U. Group has accumulated extensive expertise and knowledge over many years in the fields of infectious disease-related diagnostic reagents and testing services. Building on this foundation, we contribute to people's health by supporting the early detection of infectious diseases and appropriate medical decision-making.



- Deployment of Rapid Test Kits for Infectious Diseases such as Flu

- Expansion of Testing Items for Tropical Infectious Diseases, Including Dengue Fever and Other NTDs*

* NTDs: Neglected Tropical Diseases

- Testing Infrastructure Capable of Responding to Unexpected Infectious Disease Outbreaks

In addition to infectious diseases, we are focusing on disease areas such as metabolic disorders, autoimmune diseases, and rare diseases.




OUR BUSINESS

Three Business Segments and the Sources of Value Creation

H.U. Group operates three business segments:

In Vitro Diagnostics, Lab Testing and its Related Services, and Healthcare-Related Services.

In addition, the Group identifies the foundations supporting these three business segments as sources of value creation, and through these strengths, provides products and services that support patients throughout their Patient Journey.



IVD

In Vitro Diagnostics

The Innovation Engine Powering Global Diagnostics

Diagnostic Technologies and Content for Global Partnerships

Fujirebio Group develops break-through biomarker and diagnostic content that power critical tests across the globe's leading diagnostic platforms. Fujirebio Group's research infrastructure and networks in Japan, Europe, and the United States make up an integrated development system that reaches from basic research to full commercialization. The unique content resulting from this process brings unique value beyond the individual products and contributes to transforming patient journeys across the globe through life-changing diagnostics. Since Fujirebio Group developed the world's first diagnostic test for syphilis in 1966, it has created a wide range of critical diagnostic content in the fields of infectious diseases and oncology used today in many of the world's most trusted IVD tests. More recently, a Fujirebio Group diagnostic product that enables the detection of Alzheimer's disease from a blood sample became the first of its kind in the world to receive approval from the FDA in the United States. This new diagnostic technology is expected to contribute to better patient care, not only by reducing the physical burden on patients but also by expanding the possibilities for early diagnosis and drug discovery and development.



A Platform Supporting Clinical Testing

Fujirebio Group developed its proprietary Lumipulse® series of fully automated chemiluminescent enzyme immunoassay systems in 1992, followed by the ESPLINE® series of instrument-free rapid diagnostic tests in 1997. These platforms are utilized not only by healthcare institutions but also by clinical laboratories, including the H.U. Bioness Complex. Through H.U. Group's network, Fujirebio Group's content and technologies support clinical practice throughout the diagnostic and treatment process.

Contributing to Healthcare Worldwide through Partnerships

Our innovative diagnostic technologies are delivered through global partnerships to healthcare providers around the world, helping bring advanced diagnostics closer to patients. Fujirebio Group's CDMO (Contract Development and Manufacturing Organization) business goes beyond traditional contract manufacturing alone, flexibly adapting to the diverse business environments of each partner company and enabling collaboration at various stages, from early-stage research and development through commercial manufacturing. Through this partnership-driven business model, Fujirebio Group extends the reach of its diagnostic technologies to healthcare providers and patients worldwide, including regions and clinical settings that would otherwise be beyond its direct reach. As a biomarker and diagnostic content provider, Fujirebio Group contributes to expanding access to essential testing by providing the core technologies and expertise that power diagnostic solutions worldwide.

[Please click for more details](#)



[Group Companies]

Fujirebio Holdings, Inc.
FUJIREBIO INC.
Fujirebio Diagnostics Japan, Inc.
Advanced Life Science Institute, Inc.
Fujirebio Diagnostics, Inc. (US)
Fujirebio Diagnostics AB (Sweden)
CanAg Diagnostics (Beijing) Co., Ltd.
Plasma Services Group, Inc. (US)
Fujirebio Europe N.V. (Belgium)
Fujirebio Italia S.r.L.
Fujirebio Germany GmbH
Fujirebio Iberia SL (Spain)
Fujirebio France SARL
Fluxus, Inc. (US)
Fujirebio China Co., Ltd.

LTS

Lab Testing and its related Services

Providing Comprehensive Testing Services to Medical Institutions for over a Half Century

One of the World's Largest Clinical Laboratory Supporting Healthcare Across Japan

At state-of-art clinical laboratories, including the H.U. Bioness Complex, one of the largest laboratories, which becomes fully operational in 2023, SRL collect specimens from medical institutions across Japan and performs a wide range of tests. By Utilizing the advanced equipment and AI-driven workflow optimization, and automation, we provide high-quality, rapid testing service and proceeding hundreds of thousands of tests every day. Leveraging its long-standing expertise, SRL is particularly recognized for its strengths in esoteric testing, including oncology, genetic, infectious disease,

bacteriology, and virology testing, supporting healthcare providers throughout nationwide.


Contributing to the Advancement of Cutting-Edge Healthcare

As personalized medicine continues to advance, expectations for testing technologies are increasing. SRL is committed to providing advanced testing services that support clinical decision-making, including companion diagnostics-related tests, which plays a critical role in cancer treatment. In addition, we also focus on omics-based analysis, including Whole Genome Sequencing (WGS) and proteome analysis, which contribute to the development of new diagnostic methods.

Expanding Digital Healthcare Solutions (Healthcare x ICT Services)

In response to the growing demand for enhanced community healthcare and preventive medicine, SRL is developing new solutions that integrate healthcare solutions and ICT (Information and Communication Technology). By promoting the digitalization of testing information and providing both healthcare provider-focused SaaS (Software as a Service) and PHR (Personal Health Record) services for consumers through H.U. Group, SRL supports more effective utilization of diagnostic data and improved operational efficiency across healthcare settings.

[Please click for more details](#)



[Group Companies]

SRL, Inc.
Nihon Rinsho, Inc.
Tokyo Central Pathology Laboratory, Inc.
H.U. Wellness, Inc.
Japan Institute of Foods Ecology, Inc.
SRL & Shizuoka Cancer Center Collaborative Laboratories, Inc.
H.U. POCKET, Inc.
H.U. Cells, Inc.
Ishinban, Inc.
H.U. America, Inc.
KBBM, Inc.
St. Luke's SRL Advanced Clinical Research Center, Inc.



Healthcare-related Services

One-Stop Comprehensive Support for Hospitals and Home-Based Patients to Meet a Wide Range of Needs

Wide Range of Services Supporting Hospital Operations

Nihon Stery specializes in on-site sterilization at the central sterile services department in hospitals and off-site sterilization at our sterilization centers (eight domestic centers). We also offer a range of other services, including operating room support, endoscopy room support, medical equipment maintenance and inspection, and materials management and transportation services. By providing total support for important tasks related to hospital operations, including the sale of medical equipment, supplies, and consumables related to sterile services department and operating rooms, we not only enhance operational efficiency and leverage economies of scale but also contribute to creating an environment where physicians and nurses can focus on patient care.

Stable Operational Support through Expertise and Quality Management

As a medical partner, Nihon Stery is working to enhance the expertise of its human resources, improve the quality of its operations, and increase the added value of its services in response to changes in the healthcare environment and increasingly sophisticated needs. By building a highly skilled professionals and providing solutions that leverage accumulated know-how and data, we support the stable operation of healthcare facilities. Furthermore, to enhance the quality, transparency, and traceability of our services, we are advancing the quality management systems at our sterilization centers while standardizing and visualizing business processes and promoting continuous quality management activities.

Home Healthcare and Care Business Supporting Life in Familiar Surroundings

“I want to be true to myself and live in familiar surroundings.” In response to such needs, StarQ GAIA operates home healthcare and care business. We provide total support for users, with a focus on home-visit nursing, where nurses visit individuals’ homes to provide various types of care. We also offer care management services and operate home care services. In response to the growing and diversifying needs of users and their families, we are strengthening our service delivery system to provide safer, higher-quality home healthcare and care. In recent years, we have started expanding our services to meet the growing demand for more comprehensive care, including services not covered by insurance.



Please click for more details



[Group Companies]

Nihon Stery, Inc.
StarQ GAIA Inc.
GAIA medicare Inc.
StarQ care Inc.


Creating New Value by Leveraging the Strengths of the H.U. Group

H.U. Group is driving collaboration among its R&D organizations across the Group. For example, H.U. Group Research Institute (HRI) incorporates diverse new technologies at an early stage and promotes the development of products and services in emerging technological fields. At the same time, the R&D division of the IVD business has built technological foundations in diagnostic reagent and system development. By combining with the expertise of the R&D division of the LTS business in evaluating and introducing new technologies, the Group can accelerate the development and market introduction of distinctive new products and innovative services. While each R&D organization continues to focus on its respective activities, they strengthen collaboration in strategy, issues, and resources, creating new value by leveraging the Group's strengths and contributing further to society, medicine, and healthcare.

Enhancing Testing Performance and Ensuring a Stable Supply with In-House Reagents


Nucleic acid extraction reagents used in the pre-processing steps of testing had previously been imported from overseas. By developing and manufacturing these reagents in Japan through collaboration between H.U. Group Research Institute and the R&D organizations of the IVD and LTS businesses, H.U. Group has achieved a stable domestic supply. In addition, the Group has developed nucleic acid amplification test reagents contributing to improvements in testing service quality through enhanced testing productivity and performance, as well as reduced TAT*.

*TAT: Turn Around Time. The time from specimen receipt to the reporting of test results.



Improving Testing Process Efficiency through AI

Chromosome testing is an examination used to identify abnormalities in the number and structure of chromosomes. We have developed and implemented an in-house AI system that supports the pre-processing steps of this test, including the isolation and arrangement of chromosomes from microscopic images. This AI system has reduced more than 10,000 hours of work annually and has enabled technicians to focus more on the identification of abnormalities.



Resolution of Social Issues

As a company that supports healthcare, H.U. Group is committed to addressing social issues through its business activities and aims to create a society where everyone can access healthcare with peace of mind.

Six Materialities



Resolution of Social Issues through Our Businesses



Creation of Innovation



Human Resource Development that Creates New Value



Mitigation of Environmental Impacts



Establishment of a Sustainable Value Chain



Strengthening of Corporate Governance



Resolution of Social Issues through Our Business

Role as a Healthcare Infrastructure

At H.U. Bioness Complex, the core facility of H.U. Group, we not only foster the co-creation of new value in healthcare, but we are also strengthening our BCP measures so that our operations can continue even in the event of a disaster. As a result, the Laboratory and R&D buildings are able to continue operations for three days (72 hours) even after a major earthquake.



Electricity: Emergency generators

Two 3,750kVA large-scale emergency generators.



Water storage: Laboratory Building water tank

Large-capacity water storage tank (600 tons)
Large-capacity drainage tanks, well water facilities, etc.

Please click for more details



Resolution of Social Issues through Our Business

Improving Access to Healthcare and Contributing to Global Health

Beyond Japan, we are also working to address global health challenges. In particular, infectious disease control is an important theme that is directly linked to the health of people around the world. Since developing the world's first syphilis testing product in 1966, the Group has built strong expertise in the field of infectious diseases and continued to contribute to addressing challenges in this area.



Toward the Development of a New Diagnostic Method for Tuberculosis / Supported from the GHIT Fund* Grant

Tuberculosis (TB) remains one of the leading causes of death from infectious diseases worldwide, and there is an urgent need for rapid and highly accurate diagnostic methods. With support from the GHIT Fund*, the Fujirebio Group is developing diagnostic reagents that detect Mycobacterium tuberculosis in urine samples, as well as compact portable devices for rapid diagnosis, leveraging ultrasensitive detection technologies.

* Global Health Innovative Technology Fund

Approval of a Rapid Test for Hepatitis B in the Republic of The Gambia

According to the World Health Organization (WHO), more than 250 million people worldwide are chronically infected with hepatitis B virus (HBV), and HBV infection is also considered to be highly prevalent in the Republic of The Gambia. The Fujirebio Group has received product registration approval for its rapid test for hepatitis B, "ESPLINE™ HBeAg-hs," in the country. Through this initiative, the Group aims to contribute to the prevention of mother-to-child transmission of hepatitis B and to the development of healthcare systems in The Gambia.

Aim to Be a Company Where Employees Are Willing to Build Long-Term Careers

Creating an Environment Where Each Individual Can Grow, Take on Challenges, and Thrive with Pride

To achieve sustainable growth, H.U. Group recognizes that it is essential to create an environment where each employee can fully realize their potential and continue to work with enthusiasm and vitality.

We are expanding opportunities for employees to take on challenges regardless of age or position, while building an organization where diverse talent can thrive by leveraging their individual strengths.

By promoting human capital management that creates a virtuous cycle between employee growth and corporate growth, we aim to become a company where employees willing to work for the long term.



Developing Talent That Creates New Value

By fostering a shared commitment to our corporate philosophy, we create an environment where every employee can find purpose in their work and continue to take on new challenges. Through diverse growth opportunities, we aim to develop talent who think independently and drive transformation and value creation.

* The following two items are regularly monitored through the engagement survey.

Commitment to
the Corporate Philosophy

Growth Opportunity



Workplace Environment That Supports Growth and New Challenges

We are creating a workplace where employees can remain healthy, be themselves, and continue to thrive over the long term.



The brands under
KENKO Investment for
Health

Selected for Three
Consecutive Years



Outstanding
Organizations of KENKO
Investment for Health
(White 500)

Selected for Five
Consecutive Years



D&I AWARD
the Highest Evaluation
"Best Workplace"

Selected for Two
Consecutive Years

Please click for more details




ABOUT H.U.GROUP

Overview of Business Segments


LTS
Lab Testing and its related Services
157.3 billion yen

IVD
In Vitro Diagnostics
60.7 billion yen


HS
Healthcare-related Services
29.3 billion yen




Consolidated Net Sales




Number of Employees As of March 2026



Patents



R&D Costs FY2025



CORPORATE PROFILE

Corporate name	H.U. Group Holdings, Inc.
Headquarters	Akasaka Intercity AIR, 1-8-1, Akasaka, Minato-ku, Tokyo 107-0052, Japan TEL: +81-3-6279-0801 (switchboard number) Representative Executive Officer, President and Group CEO Goki Ishikawa
Foundation	December 18, 1950
Capital stock	9,309 million yen (as of March 31, 2026)
Permanent employees	5,157 (Consolidated) (as of March 31, 2026)
Listed stock market	Tokyo Stock Exchange, Prime Market (Stock Code: 4544)
Management structure	Company with three committees under the Companies Act of Japan
Main subsidiaries	FUJIREBIO INC., SRL, Inc. and Nihon Stery, Inc.

[The H.U. Group's official homepage](#)

[For more details on Directors & Officers](#)

GROUP DATA

